Telehealth Platform Hims Expands Into Testosterone Replacement Therapy

A New Phase for Telehealth

Telehealth company Hims has announced the launch of a new service providing testosterone replacement therapy (TRT) for cisgender men. The company, which initially gained market share through hair loss and erectile dysfunction treatments, is expanding its clinical offerings to address what its leadership describes as an underdiagnosed and misunderstood medical condition.

Diagnostic Process and Requirements

Unlike standard digital prescriptions that may rely solely on questionnaires, testosterone therapy requires "synchronous" care due to the hormone's classification as a controlled substance. Hims plans to utilize an at-home blood collection device manufactured by Tasso. This wearable, single-use device uses microneedles to collect a small sample, which is then sent to a laboratory to analyze 21 different biomarkers, including testosterone, triglycerides, and thyroid hormones.

According to Hims, simply having low blood-work numbers will not trigger a prescription. Peter Stahl, a senior vice president of men’s health at Hims, stated that patients who are asymptomatic will not receive treatment. Clinicians are expected to evaluate laboratory results in conjunction with a patient's reported symptoms and full medical history to reach a diagnosis of hypogonadism.

Medical Context and Safety

Testosterone therapy carries significant medical considerations. Dr. Mohit Khera, director of the Laboratory for Andrology Research at Baylor College of Medicine, noted that appropriate monitoring is essential. He emphasized that testosterone therapy can cause infertility, meaning it is not indicated for men currently attempting to conceive.

The industry faces a complex landscape. Research published in 2022 highlighted concerns regarding the "Wild West" nature of online testosterone clinics, with some studies suggesting that certain providers were willing to prescribe the hormone even to patients reporting normal levels. Hims officials state they aim to differentiate their service by focusing on patients who meet specific clinical criteria for deficiency rather than marketing the treatment as a general anti-aging or lifestyle enhancement tool.

Understanding the Cultural Shift

Testosterone has gained significant cultural and political visibility recently, with increased public discourse surrounding "low T" and its impact on male health. Hims commissioned a survey of 2,000 American men, which indicated that while interest in discussing testosterone treatment is growing, stigma regarding its use remains a barrier for many patients. The company views the testing service as an entry point to engage men in broader conversations about their overall health.

For more information on the announcement and the company's clinical approach, visit the official source coverage at https://www.wired.com/story/telehealth-giant-hims-testosterone-therapy/.